...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
【24h】

Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.

机译：FAS和FASL基因的多态性与早期非小细胞肺癌的生存率。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: This study was conducted to investigate the impact of functional polymorphisms in the FAS and FASL genes on the survival of early stage non-small cell lung cancer (NSCLC) patients. EXPERIMENTAL DESIGN: Three hundred and thirty-eight consecutive patients with surgically resected NSCLC were enrolled. The FAS -1377G>A (rs2234767) and -670A>G (rs1800682) and FASL -844C>T (rs763110) polymorphisms were investigated. Immunohistochemistry was used to assess FAS protein expression in tumors. The genotype and haplotype associations with survival were analyzed using Cox proportional hazards model, Kaplan-Meier method, and the log-rank test. RESULTS: Patients with the GG and combined AG+GG genotypes of the FAS -670A>G locus had a significantly decreased survival when compared with patients with the AA genotype [adjusted hazard ratio=1.71, 95% confidence interval (95% CI)=1.06-2.77, and P=0.03; and adjusted hazard ratio=1.48, 95% CI=1.01-2.20, and P=0.047, respectively]. In addition, the FAS -1377G/-670G and -1377A/-670G haplotypes exhibited a significantly lower survival compared with the -1377G/-670A haplotype (adjusted hazard ratio=1.87, 95% CI=1.20-2.91, and P=0.006; and adjusted hazard ratio=1.31, 95% CI=1.05-1.65, P=0.02, respectively). Strongly positive FAS immunostaining was significantly less frequent in patients with the FAS -670 AG+GG genotype than in patients with the -670 AA genotype (4.5% versus 10.8%; P=0.04). CONCLUSION: The FAS -670A>G polymorphism may affect survival in early-stage NSCLC. The analysis of the FAS -670A>G polymorphism can help identify patients at high risk for a poor disease outcome.
机译：目的：本研究旨在研究FAS和FASL基因中的功能多态性对早期非小细胞肺癌（NSCLC）患者生存的影响。实验设计：入选了338例连续手术切除的非小细胞肺癌患者。研究了FAS -1377G> A（rs2234767）和-670A> G（rs1800682）和FASL -844C> T（rs763110）多态性。免疫组织化学用于评估肿瘤中FAS蛋白的表达。使用Cox比例风险模型，Kaplan-Meier方法和对数秩检验分析了基因型和单倍型与生存的关联。结果：与AA基因型患者相比，具有FAS -670A> G位点的GG基因型和AG + GG组合基因型患者的生存率显着降低[校正风险比= 1.71，95％置信区间（95％CI）= 1.06-2.77，且P = 0.03;调整后的危险比= 1.48，95％CI = 1.01-2.20，P = 0.047]。此外，与-1377G / -670A单倍型相比，FAS -1377G / -670G和-1377A / -670G单倍型的存活率要低得多（调整后的危险比= 1.87，95％CI = 1.20-2.91，P = 0.006） ;调整后的危险比分别为1.31、95％CI = 1.05-1.65，P = 0.02）。具有FAS -670 AG + GG基因型的患者中，强阳性FAS免疫染色的频率明显低于具有-670 AA基因型的患者（4.5％比10.8％; P = 0.04）。结论：FAS -670A> G多态性可能影响NSCLC早期生存。 FAS -670A> G基因多态性的分析可帮助确定罹患不良疾病预后的高风险患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号